SG11201805286RA - α,β-UNSATURATED AMIDE COMPOUND - Google Patents
α,β-UNSATURATED AMIDE COMPOUNDInfo
- Publication number
- SG11201805286RA SG11201805286RA SG11201805286RA SG11201805286RA SG11201805286RA SG 11201805286R A SG11201805286R A SG 11201805286RA SG 11201805286R A SG11201805286R A SG 11201805286RA SG 11201805286R A SG11201805286R A SG 11201805286RA SG 11201805286R A SG11201805286R A SG 11201805286RA
- Authority
- SG
- Singapore
- Prior art keywords
- optionally substituted
- amide compound
- represents hydrogen
- unsaturated amide
- lower alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
The present invention provides an α,β -unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer 5 activity and the like represented by the following formula (I): [Chemical formula 1] [wherein, “A” represent s optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, 10 R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen 15 atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015252234 | 2015-12-24 | ||
PCT/JP2016/088476 WO2017111076A1 (en) | 2015-12-24 | 2016-12-22 | α, β UNSATURATED AMIDE COMPOUND |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805286RA true SG11201805286RA (en) | 2018-07-30 |
Family
ID=59090542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805286RA SG11201805286RA (en) | 2015-12-24 | 2016-12-22 | α,β-UNSATURATED AMIDE COMPOUND |
Country Status (11)
Country | Link |
---|---|
US (2) | US10787428B2 (en) |
EP (1) | EP3401309A4 (en) |
JP (3) | JP6983661B2 (en) |
KR (1) | KR20180094923A (en) |
CN (1) | CN108430972B (en) |
AU (3) | AU2016379292B2 (en) |
CA (2) | CA3009159C (en) |
MY (1) | MY196809A (en) |
SG (1) | SG11201805286RA (en) |
TW (2) | TWI740873B (en) |
WO (1) | WO2017111076A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201912770SA (en) * | 2017-06-23 | 2020-01-30 | Kyowa Kirin Co Ltd | a, ß-UNSATURATED AMIDE COMPOUND |
US20210347777A1 (en) | 2018-10-23 | 2021-11-11 | Basf Se | Tricyclic pesticidal compounds |
TW202108559A (en) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead inhibitors and uses thereof |
US11274082B2 (en) | 2019-05-31 | 2022-03-15 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
JP2022541274A (en) * | 2019-07-19 | 2022-09-22 | ブリッドジーン バイオサイエンシズ インコーポレイテッド | inhibitor of tyrosine kinase |
TW202128161A (en) | 2019-10-18 | 2021-08-01 | 美國加利福尼亞大學董事會 | Compounds and methods for targeting pathogenic blood vessels |
IL293735A (en) * | 2019-12-24 | 2022-08-01 | Dana Farber Cancer Inst Inc | Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof |
MX2022012852A (en) | 2020-04-14 | 2022-11-07 | Basf Se | Tricyclic pesticidal compounds. |
US20240025856A1 (en) | 2020-09-30 | 2024-01-25 | Katholieke Universiteit Leuven | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer |
WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
KR20230149885A (en) | 2021-01-25 | 2023-10-27 | 이케나 온콜로지, 인코포레이티드 | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide TEAD inhibitor with an EGFR inhibitor and/or MEK inhibitor for use in the treatment of lung cancer |
IL307673A (en) | 2021-04-16 | 2023-12-01 | Ikena Oncology Inc | Mek inhibitors and uses thereof |
WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3849458A (en) | 1966-01-21 | 1974-11-19 | Incentive Res & Dev Ab | Method for deuterating organic compounds |
JPS61148141A (en) | 1984-12-21 | 1986-07-05 | Mitsubishi Rayon Co Ltd | Production of deuterated methyl acrylate or deuterated methyl methacrylate |
JPS61275241A (en) | 1985-05-29 | 1986-12-05 | Mitsubishi Rayon Co Ltd | Production of deuterated acrylic acid or methacrylic acid |
JPS61277648A (en) | 1985-06-03 | 1986-12-08 | Mitsubishi Rayon Co Ltd | Production of deuterated acrylic acid or deuterated methacrylic acid |
DE3701302A1 (en) | 1987-01-17 | 1988-07-28 | Hoechst Ag | METHOD FOR PRODUCING DEUTERED ORGANIC COMPOUNDS |
CA2021194A1 (en) | 1989-07-17 | 1991-01-18 | Naoki Inui | Rubber composition useful for tires |
TW416953B (en) | 1996-09-25 | 2001-01-01 | Takeda Chemical Industries Ltd | Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US6090854A (en) | 1998-03-20 | 2000-07-18 | Bristol-Meyers Company | Aryloxyanilides and related compounds |
CA2362401A1 (en) * | 1999-02-04 | 2000-08-10 | Paul Fleming | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
PL350920A1 (en) * | 1999-04-21 | 2003-02-10 | American Cyanamid Co | Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases |
US6548496B2 (en) | 1999-04-21 | 2003-04-15 | American Cyanamid Company | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
WO2001018006A1 (en) | 1999-09-09 | 2001-03-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6624159B2 (en) | 2000-07-12 | 2003-09-23 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
DE10130397A1 (en) | 2001-06-23 | 2003-01-09 | Bayer Cropscience Gmbh | Herbicidally substituted pyridines, processes for their preparation and their use as herbicides and plant growth regulators |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
EP1483295B1 (en) * | 2002-03-01 | 2008-12-10 | Immunomedics, Inc. | Rs7 antibodies |
US20040122048A1 (en) | 2002-10-11 | 2004-06-24 | Wyeth Holdings Corporation | Stabilized pharmaceutical composition containing basic excipients |
KR20050122199A (en) * | 2003-01-23 | 2005-12-28 | 티.케이. 시그널 리미티드 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis |
EP1636195A1 (en) | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
CN100545161C (en) * | 2003-08-15 | 2009-09-30 | 中国科学院上海药物研究所 | Heterocycle derivative, preparation method and its usage |
US7399865B2 (en) * | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
US7858640B2 (en) | 2005-09-30 | 2010-12-28 | Pulmagen Therapeutics (Asthma) Limited | Quinolines and their therapeutic use |
CN101405280B (en) * | 2006-01-20 | 2012-11-14 | 先灵公司 | Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors |
CA2637897A1 (en) * | 2006-01-20 | 2007-07-26 | Schering Corporation | Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors |
CN101245050A (en) | 2007-02-14 | 2008-08-20 | 上海艾力斯医药科技有限公司 | 4-aniline quinazoline derivative salt |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
CA2920996A1 (en) | 2007-10-19 | 2009-04-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
CN101638383B (en) | 2008-07-29 | 2013-07-10 | 北大方正集团有限公司 | Quinoline as well as pharmaceutical composition and use thereof |
WO2010036928A1 (en) * | 2008-09-26 | 2010-04-01 | Takeda Pharmaceutical Company Limited | Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation) |
AU2010284255B2 (en) * | 2009-08-17 | 2016-11-17 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
WO2011025546A1 (en) | 2009-08-31 | 2011-03-03 | Massachusetts Institute Of Technology | 1, 2, 3-triazole containing protein kinase sensors |
CN106478497B (en) * | 2010-10-18 | 2020-05-08 | 拉夸里亚创药株式会社 | Arylamine derivatives as TTX-S blockers |
CN101983961B (en) | 2010-11-24 | 2012-05-09 | 浙江启明生化科技有限公司 | Preparation method of 5-amino-2-methyl quinoline |
WO2012122058A2 (en) | 2011-03-04 | 2012-09-13 | Newgen Therapeutics, Inc. | Alkyne substituted quinazoline compound and methods of use |
CN103501612B (en) * | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | The compound that cell is bred in cancer caused by suppression EGF-R ELISA |
CN102816175B (en) * | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | A kind of heterocycle pyridine compounds, its intermediate, preparation method and purposes |
CA2833771C (en) | 2011-06-10 | 2021-08-03 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
CN102311395B (en) * | 2011-07-05 | 2014-04-16 | 张爱华 | Quinazoline ring substituted diphenylurea derivative and its purpose |
JP6382108B2 (en) | 2011-11-30 | 2018-08-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Novel bicyclic dihydroisoquinolin-1-one derivatives |
US9085540B2 (en) * | 2012-01-17 | 2015-07-21 | Astellas Pharma Inc. | Pyrazinecarboxamide compound |
CN104203242B (en) * | 2012-04-04 | 2017-03-15 | 杭州德润玉成生物科技有限公司 | Substituted quinolines are used as bruton's tyrosine kinase inhibitor |
SI2838883T1 (en) | 2012-04-17 | 2018-02-28 | F. Hoffmann-La Roche Ag | New phenyl-tetrahydroisoquinoline derivatives |
WO2014040555A1 (en) | 2012-09-12 | 2014-03-20 | 山东亨利医药科技有限责任公司 | Nitrogen-containing heteroaromatic ring derivative as tyrosine kinase inhibitor |
EP2968339A4 (en) * | 2013-03-15 | 2017-02-15 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
WO2014182829A1 (en) | 2013-05-09 | 2014-11-13 | Principia Biopharma Inc. | Quinolone derivatives as fibroblast growth factor inhibitors |
US9670231B2 (en) * | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
WO2015025197A1 (en) * | 2013-08-22 | 2015-02-26 | Jubilant Biosys Limited | Substituted pyrimidine compounds, compositions and medicinal applications thereof |
CN103450133B (en) | 2013-09-16 | 2015-07-08 | 中国药科大学 | Scopoletin derivatives with anti-tumor activity, and preparation method and application thereof |
WO2015051447A1 (en) | 2013-10-09 | 2015-04-16 | University Health Network | Methods and compositions for treating cancer |
CN104761544B (en) | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | The selective depressant of the important mutant of clinic of EGFR tyrosine kinase |
WO2015158310A1 (en) * | 2014-04-18 | 2015-10-22 | 山东轩竹医药科技有限公司 | Tyrosine kinase inhibitor and uses thereof |
CN111875585B (en) | 2014-06-12 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | Kinase inhibitors |
DK3157916T3 (en) | 2014-06-19 | 2019-03-18 | Ariad Pharma Inc | HETEROARYL COMPOUNDS FOR CHINESE INHIBITION |
CN105315259B (en) | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | Pyridine amine pyrimidine derivates, its preparation method and application |
CN104370825B (en) * | 2014-09-29 | 2017-04-19 | 人福医药集团股份公司 | Substituted heterocyclic compound as kinase inhibitor and its preparation method and use |
MX2017009571A (en) | 2015-01-23 | 2018-09-27 | Aclaris Therapeutics Inc | Heterocyclic itk inhibitors for treating inflammation and cancer. |
-
2016
- 2016-12-22 EP EP16878962.6A patent/EP3401309A4/en active Pending
- 2016-12-22 US US16/065,937 patent/US10787428B2/en active Active
- 2016-12-22 CN CN201680076128.3A patent/CN108430972B/en active Active
- 2016-12-22 CA CA3009159A patent/CA3009159C/en active Active
- 2016-12-22 AU AU2016379292A patent/AU2016379292B2/en active Active
- 2016-12-22 SG SG11201805286RA patent/SG11201805286RA/en unknown
- 2016-12-22 JP JP2017558282A patent/JP6983661B2/en active Active
- 2016-12-22 TW TW105142790A patent/TWI740873B/en active
- 2016-12-22 KR KR1020187017440A patent/KR20180094923A/en not_active Application Discontinuation
- 2016-12-22 WO PCT/JP2016/088476 patent/WO2017111076A1/en active Application Filing
- 2016-12-22 MY MYPI2018001047A patent/MY196809A/en unknown
- 2016-12-22 TW TW110134669A patent/TWI804987B/en active
- 2016-12-22 CA CA3228632A patent/CA3228632A1/en active Pending
-
2020
- 2020-09-28 US US17/034,604 patent/US11332455B2/en active Active
-
2021
- 2021-06-24 AU AU2021204307A patent/AU2021204307B2/en active Active
- 2021-10-28 JP JP2021176942A patent/JP7312227B2/en active Active
-
2023
- 2023-07-07 JP JP2023112517A patent/JP2023123857A/en active Pending
- 2023-08-28 AU AU2023222816A patent/AU2023222816A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3228632A1 (en) | 2017-06-29 |
EP3401309A4 (en) | 2019-11-27 |
CN108430972B (en) | 2022-12-27 |
WO2017111076A1 (en) | 2017-06-29 |
EP3401309A1 (en) | 2018-11-14 |
JP2022009699A (en) | 2022-01-14 |
AU2016379292A1 (en) | 2018-07-12 |
JP6983661B2 (en) | 2021-12-17 |
JPWO2017111076A1 (en) | 2018-10-18 |
TW202202483A (en) | 2022-01-16 |
AU2021204307B2 (en) | 2023-06-01 |
KR20180094923A (en) | 2018-08-24 |
US10787428B2 (en) | 2020-09-29 |
CN108430972A (en) | 2018-08-21 |
AU2023222816A1 (en) | 2023-09-14 |
AU2016379292B2 (en) | 2021-03-25 |
TWI740873B (en) | 2021-10-01 |
CA3009159C (en) | 2024-03-19 |
US11332455B2 (en) | 2022-05-17 |
TW201736347A (en) | 2017-10-16 |
AU2021204307A1 (en) | 2021-07-29 |
US20210380551A1 (en) | 2021-12-09 |
MY196809A (en) | 2023-05-03 |
CA3009159A1 (en) | 2017-06-29 |
JP2023123857A (en) | 2023-09-05 |
JP7312227B2 (en) | 2023-07-20 |
TWI804987B (en) | 2023-06-11 |
US20190010136A1 (en) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805286RA (en) | α,β-UNSATURATED AMIDE COMPOUND | |
PH12016501813B1 (en) | 1,3-benzodioxole derivative | |
PH12018501179A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
PH12020500673A1 (en) | Compounds | |
WO2017019804A3 (en) | Compounds and methods for kinase modulation, and indications therefor | |
PH12017502171A1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
PH12016502358B1 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
NZ719968A (en) | Pesticidal compositions and related methods | |
MX2017005158A (en) | Heterocyclic derivative having ampk activating effect. | |
MX2020002430A (en) | Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds. | |
MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
MX2017002275A (en) | Azaindole derivative having ampk-activating effect. | |
MX2022006783A (en) | New methylquinazolinone derivatives. | |
PH12020500341A1 (en) | Pentacyclic compound | |
MY198004A (en) | Antitumoral compounds | |
MX2018001517A (en) | Substituted guanidine derivative. | |
PH12020550403A1 (en) | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof | |
NZ738953A (en) | Production method for nitrogen-containing heterocyclic compound, and intermediate of said nitrogen-containing heterocyclic compound | |
PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
MY193239A (en) | Novel b-lactamase inhibitors | |
MY185558A (en) | Pyrido-oxazinone derivatives as tnap inhibitors | |
MY201356A (en) | Therapeutic or prophylactic agent for peripheral neuropathies | |
MX2014002210A (en) | Pyrrolidine-3-ylacetic acid derivative. |